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http://dx.doi.org/10.1016/j.ccell.2014.08.017SUMMARYPIK3R1 (p85a regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demon-
strate that the most common recurrent PIK3R1mutation PIK3R1R348* and a nearby mutation PIK3R1L370fs, in
contrast towild-type andmutations in other regions ofPIK3R1, confers an unexpected sensitivity toMEK and
JNK inhibitors in vitro and in vivo. Consistent with the response to inhibitors, PIK3R1R348* and PIK3R1L370fs
unexpectedly increase JNK and ERK phosphorylation. Surprisingly, p85a R348* and L370fs localize to the
nucleus where the mutants provide a scaffold for multiple JNK pathway components facilitating nuclear
JNK pathway activation. Our findings uncover an unexpected neomorphic role for PIK3R1R348* and neigh-
boring truncation mutations in cellular signaling, providing a rationale for therapeutic targeting of these
mutant tumors.INTRODUCTION
Specific molecular aberrations in a cancer gene can have func-
tional consequences that determine therapeutic sensitivity
(Chen et al., 2004; Lutzky et al., 2008; Lynch et al., 2004). Impor-
tantly, specific mutations can exhibit hypomorphic (decreased
function), hypermorphic (increased function), or less understood
neomorphic (gain-of-function) effects. Indeed,mutated IDH1 and
IDH2 and a number of other oncogenicmutations are neomorphs
(Ward et al., 2010). If neomorphic mutations are common in
human tumors, this will require a systematic characterization of
underlying mechanisms and therapeutic liabilities engendered
by the neomorphic mutations if we are to optimally capitalize
on broad genomic characterization of patient tumors and imple-
mentation of personalized cancer therapy.
PIK3R1mutation represents one of the most common aberra-
tions being the 11th most commonly mutated gene across 4,429
tumors covering 20 diseases in The Cancer Genome AtlasSignificance
Previously characterizedmutants of the p85a regulatory subun
activating p110 or decreasing PTEN function. We demonstrate
neomorphs that result in selective activation of components of
and JNK inhibitors. These neomorphic mutations represent t
endometrial and colon cancers and could potentially be bio
and JNK pathways in tumors with these mutations. Our find
may need to be conditioned on the specific mutation in the ca
C(TCGA) database. PIK3R1 mutations are particularly prevalent
in endometrial (20% and 34% in our and TCGA data sets,
respectively; Cheung et al., 2011; Kandoth et al., 2013) and colon
cancers (4%; TCGA; Cerami et al., 2012). We recently demon-
strated that the most common recurrent PIK3R1 mutation,
R348*, which accounts for approximately 10% of all PIK3R1
mutations in endometrial and colon cancers, acts as a gain-of-
function mutation by increasing survival in BaF3 murine myeloid
cells (Cheung et al., 2011). PIK3R1, which encodes the
p85a subunit of PI3K, functions primarily as a regulator of the
p110a catalytic product of the PIK3CA locus. Importantly,
the PIK3R1R348* truncation mutation produces a protein that
cannot bind to p110a and thus the gain-of-function activity of
PIK3R1R348* is unlikely to involve altered p110a activity. Whether
additional patient-derived mutations in PIK3R1 in proximity to
R348 (Cerami et al., 2012; Cheung et al., 2011) will also act as
gain-of-function mutations is not yet known. Based on the fre-
quency of PIK3R1R348* and neighboring mutations as well asit of PI3K exclusively target PI3K pathway activation either by
that PIK3R1R348* and neighboring truncation mutations are
the MAPK pathway leading to therapeutic sensitivity to MEK
he most common subset of recurrent PIK3R1 mutations in
markers of responsiveness to inhibitors targeting the ERK
ings also suggest that the selection of targeted therapies
ncer gene rather than on the cancer gene alone.
ancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc. 479
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p85a Neomorphic Mutants Activate MAPK Pathwaythe gain-of-function activity of PIK3R1R348*, we investigated the
functional consequences of PIK3R1 mutations within the region
on cellular signaling and cellular phenotypes aswell as therapeu-
tic liabilities.
RESULTS
PIK3R1R348* and PIK3R1L370fs Render Cells Sensitive to
Specific MAPK Pathway Inhibitors
Having previously demonstrated that PIK3R1R348* is a gain-of-
function mutation in BaF3 cells, we undertook a BaF3 differential
cytotoxicity screen to examine whether specific PIK3R1 muta-
tionswould alter sensitivity toward a collection of 145 compounds
targetingmajor signaling pathways. The normally interleukin 3 (IL-
3)-dependent BaF3 cells were rendered IL-3-independent by sta-
ble expression of p85amutants that activate signaling pathway(s)
able to drive survival of BaF3. Inhibitors that target signaling
pathway(s) induced by the mutant would cause growth inhibition
or cell death that can be rescued by exogenous IL-3, providing a
‘‘counterscreen’’ for nonspecific effects of the inhibitor. The in-
hibiting concentration 25% (IC25) and inhibiting concentration
50% (IC50) values for each compound across the cell lines are
listed in Table S1 (available online). Strikingly, PIK3R1E160* and
PIK3R1R348* mutations rendered the cells sensitive to different
PI3K pathway inhibitors (Figure S1A). Exogenous IL-3 rescued
cells from the inhibition, consistent with an on-target effect as
compared to nonspecific toxicity. Interestingly, PIK3R1E160*,
which we have demonstrated to alter PTEN stability and activity
(Cheung et al., 2011), led to sensitivity to a downstream inhibitor
of the pathway (rapamycin) but not an inhibitor of p110
(GDC0941), which is proximal to PTEN. In contrast, PIK3R1R348*
engendered sensitivity to an AKT inhibitor MK2206, but not
rapamcyin or GDC0941. If this sensitivity is reflected in patient
tumors, differential therapeutic approaches will be required for
these and potentially other PIK3R1 mutations. Intriguingly,
KRASG12D-expressing BaF3 cells were sensitive to rapamycin
and MK2206 potentially due to the interaction of KRas G12D
with p110 (Rodriguez-Viciana et al., 1994).
The advantage of probing the cell lines with a large ‘‘informer’’
library is the potential to identify unexpected therapeutic liabil-
ities. Indeed, BaF3 cells expressing PIK3R1R348* were sensitive
to multiple MEK (PD0325901, AZD6244, PD98059, CI1040,
and hypothemycin) and JNK inhibitors (SP600125, BI78D3,
and AEG3482; Figure 1A; Figure S1A), which was again reversed
by IL-3. Strikingly, sensitivity to MEK and JNK inhibitors was not
altered in cells expressing PIK3R1E160* or known gain-of-func-
tion PIK3R1 mutations (DKRMNS560 del, R574fs, and T576
del; Cheung et al., 2011; Quayle et al., 2012; Figure 1A; Figures
S1A and S1B). In contrast, KRASG12D conferred sensitivity to
MEK and p38 MAPK inhibitors, but not JNK inhibitors (Fig-
ure 1A; Figure S1A). Furthermore, the oncogenic PIK3CAE545K
and PIK3CAH1047R mutants did not alter sensitivity to the MAPK
pathway inhibitors (Figure S1B).
To investigate whether truncationmutations neighboring R348
also confer sensitivity to MAPK pathway inhibitors, we used an
ovarian endometrioid cancer cell line OVK18, which carries a
naturally occurring PIK3R1L370fs mutation (see Figure 4D below
for mapping of the region required to mediate the effects engen-
dered by PIK3R1R348*). Consistent with the BaF3 screen, OVK18480 Cancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc.was sensitive to multiple MEK and JNK inhibitors, but not to the
p38 MAPK inhibitor (Table 1). Ovarian endometrioid cancer is
similar to endometrial endometrioid cancer and indeed is
thought to arise from endometriosis in the ovary (Ness, 2003),
we therefore compared OVK18 with a series of endometrial en-
dometrioid cancer cell lines. Intriguingly, endometrial endome-
trioid cancer cell lines without PIK3R1L370fs but with mutations
in PI3K and MAPK pathways that parallel those in OVK18 were
less sensitive to MAPK pathway inhibitors (Table 1; Table S3).
These results are consistent with the endogenous PIK3R1L370fs
mutation mimicking PIK3R1R348* by rendering cells sensitive to
MAPK pathway inhibitors.
PIK3R1R348* and PIK3R1L370fs Induce ERK and
JNK Activation
We next determined whether pathway activation correlates with
drug sensitivity. Consistent with the sensitivity to MEK inhibi-
tors, reverse-phase protein arrays (RPPA) revealed elevated
levels of phosphorylated MKK1 (upstream kinase of ERK1/2)
in BaF3 cells expressing PIK3R1R348* or KRASG12D (Figure 1B;
Figure S1C; Table S2). In contrast, elevated phosphorylated
JNK1/2 (p-JNK) and phosphorylated c-Jun (p-c-Jun; down-
stream substrate of JNK) occurred exclusively in PIK3R1R348*-
expressing BaF3, whereas phosphorylated p38 MAPK (p-p38
MAPK) was modestly increased in KRASG12D cells. Western
blots confirmed that PIK3R1R348* and KRASG12D markedly
increased phosphorylation of MKK1, ERK1/2 and the down-
stream substrate p90RSK (Figure 1C). PIK3R1R348* increased
phosphorylation of JNK and c-Jun but not p38 MAPK, which
was, as predicted, phosphorylated in cells expressing
KRASG12D. In contrast, PIK3R1 mutants (including PIK3R1E160*)
and PIK3CA mutants that had no effect on sensitivity to MAPK
inhibitors did not alter phosphorylation of MAPK pathway mem-
bers (Figure 1C; Figures S1D and S1E).
Strikingly, ERK and JNKwere activated upon serum starvation
or growth factor stimulation in PIK3R1L370fs mutant OVK18 cells
(Figure 2A). Note the expression of the truncation mutation in
OVK18 cells). As expected, p-p38 MAPK remained unaltered.
Importantly, the activation of ERK and JNK were mediated by
PIK3R1L370fs because two p85a siRNAs that efficiently knocked
down the L370fs protein decreased ERK and JNK phosphoryla-
tion (Figure 2A). In contrast, a siRNA that decreased expression
of WT p85a but not the L370fs mutant failed to decrease ERK
and JNK activation. It is noteworthy that although PIK3R1L370fs
induced MAPKs activation, the mutant protein was present at
low levels compared to WT p85a in OVK18, consistent with
PIK3R1L370fs acting as a gain-of-function mutation.
To further assess the generalizability of effects of PIK3R1mu-
tants onMAPK pathway activation, we expressed the mutants in
a series of endometrial cancer cell lines with WT RAS genes.
PIK3R1R348* increased phosphorylated ERK (p-ERK) and p-
JNK levels in all four endometrial cancer cell lines assessed
(Figure 2B; Figure S2A; Table S3). KRASG12D-transfected cells
showed increase in p-ERK and p-p38 MAPK. Once again,
PIK3R1 mutants that did not alter sensitivity to MAPK inhibitors
did not increase phosphorylation of MAPKs (Figure 2B; Fig-
ure S2A), reinforcing the notion that activation of pathway under-
lies drug sensitivity and highlighting the neomorphic function of
PIK3R1R348* and PIK3R1L370fs. Activation of the MAPK pathway
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Figure 1. PIK3R1R348 -Expressing Cells Display Preferential Sensitivity to MAPK Inhibitors and Elevated ERK and JNK Phosphorylation
(A) Dose-response curve of control BaF3 cells (Control), which was established after transfection of PIK3R1WT but expressed low exogenous WT p85a level, or
BaF3 cells stably expressing PIK3R1E160*, PIK3R1R348*, or KRASG12D for PD0325901, SP600125, and SB203580. Means (±SD) of duplicates from two inde-
pendent experiments are shown.
(B) Heatmap of unsupervised cluster analysis of stable BaF3 cells and selected proteins by RPPA. Red indicates higher level relative to other samples.
(C) The same set of lysates used in (B) was used for western blotting.
See also Figure S1 and Tables S1 and S2.
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p85a Neomorphic Mutants Activate MAPK PathwaybyPIK3R1R348* andPIK3R1L370fs is independent of the canonical
role of p85a in PI3K signaling because multiple PI3K pathway in-
hibitors (GDC0941, PI103, andMK2206) that effectively inhibitedCPIK3R1R348*- and PIK3R1L370fs-induced AKT phosphorylation
did not decrease phosphorylation of ERK and JNK (Figures
S2B and S2C).ancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc. 481
Table 1. IC25 and IC50 Values for MAPK Inhibitors in Tested Cell Lines
MEK Inhibitor (IC25/IC50) JNK Inhibitor (IC25/IC50)
p38 MAPK Inhibitor
(IC25/IC50)
tumor type AZD6244 PD98059 PD0325901 U0126 GSK1120212B SP600125 BI78D3 AS601245 SB203580
ECC1 endometrial 3.1/NA 5.5/NA 7.1/NA 0.2/NA 1.4/NA NA/NA NA/NA NA/NA NA/NA
HEC108 endometrial 9.8/NA NA/NA 5.5/NA 0.6/NA 0.6/NA NA/NA 4.1/NA 2.3/NA NA/NA
HEC265 endometrial NA/NA NA/NA NA/NA 1.4/NA NA/NA NA/NA NA/NA 1.1/NA NA/NA
SNGII endometrial 0.1/NA 0.4/NA 2.1/NA 0.6/7.8 1.3/NA NA/NA 1.1/NA 0.49/9.8 NA/NA
OVK18 ovarian 0.03/1.2 0.03/2.7 0.04/1.8 0.009/0.7 0.04/9.5 0.09/7.1 0.06/8.2 0.08/6.4 NA/NA
IC25 and IC50 values presented in micromoles; NA, not available, inhibition did not reach 25% or 50%.
See also Table S3.
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p85a Neomorphic Mutants Activate MAPK PathwayPIK3R1R348*-Bearing Endometrial Cell Lines and
Tumors Have High Nuclear p-ERK and p-JNK
MAPKs traffic between cellular compartments to propagate sig-
nals. Subcellular fractionation showed that p-ERK was elevated
in both the cytosol and nucleus in PIK3R1R348*- and KRASG12D-
expressing endometrial cancer cells (Figure 2B). In contrast,
p-JNK was increased primarily in the nucleus of PIK3R1R348*-
expressing cells. Accumulation of nuclear p-c-Jun was also
observed (Figure S2D), consistent with PIK3R1R348* increasing
nuclear JNK activity.
We were able to probe the effect of PIK3R1R348* on p-ERK
and p-JNK localization by immunohistochemistry of four
PIK3R1R348* mutant endometrial tumors which displayed strong
nuclear staining of both p-ERK and p-JNK. In contrast, nuclear
p-ERK and p-JNK staining of 12 non-PIK3R1R348* endometrial
tumors were less intense, regardless of mutations in other sites
in PIK3R1 and other genes in the PI3K pathway (Figures 2C
and 2D; Table S4).
PIK3R1R348* Activates Specific MAPK Kinases
MAPK kinases (MKKs) selectively activate different MAPKs (De´-
rijard et al., 1995). For instance, MKK7 exclusively activates JNK,
whereas MKK4 activates p38 MAPK and JNK (Tournier et al.,
1997). Consistent with the selective effects of PIK3R1R348* and
KRASG12D on phosphorylation of MAPKs, both PIK3R1R348*
and KRASG12D increased phosphorylated MKK1/2 (p-MKK1/2),
which phosphorylates ERK (Figure 3A). In addition, knockdown
of MKK1 and MKK2 by two independent siRNAs reversed
PIK3R1R348*- and KRASG12D-induced ERK phosphorylation
(Figure 3B; Figures S3A and S3B). In contrast, phosphorylated
MKK7 (p-MKK7) was induced by PIK3R1R348*, whereas
KRASG12D activated MKK3 and MKK4. Strikingly, knock-
down of MKK7, but not MKK4, significantly decreased JNK
phosphorylation induced by PIK3R1R348* (Figure 3B; Figures
S3A and S3B).
We further determined the localization of the activated MKKs.
In PIK3R1R348*-expressing cells, p-MKK1/2 located exclusively
in the cytosol, whereas increased p-MKK7 could only be
observed in the nucleus (Figure 3C). Intriguingly, PIK3R1R348*
also induced translocation of total MKK7 from the cytosol to the
nucleus (Figure 3C)without altering total cellular levels (Figure 3A).
The accumulation and activation of nuclear MKK7 is compatible
with JNK being directly phosphorylated in the nucleus.
MKK1/2 is regulated by RAF family kinases. Knockdown of
B-Raf decreased p-MKK1/2 and p-ERK induced by PIK3R1R348*482 Cancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc.or KRASG12D (Figure 3D; Figures S3C and S3D). In contrast, c-
Raf or A-Raf siRNAs had no detectable effect on PIK3R1R348*-
induced MKK1/2 or ERK phosphorylation although the proteins
were efficiently depleted by the siRNAs and c-Raf siRNAs did
decrease KRASG12D-induced p-MKK1/2 and p-ERK (Figure 3D;
Figures S3D and S3E). In addition, B-Raf activation as indicated
by phosphorylation at threonine and serine residues was
increased in PIK3R1R348*-expressing cells (Figure 3E). Thus B-
Raf appears to be a critical intermediary between PIK3R1R348*
and ERK signaling activation.
The MLK serine/threonine protein kinase family including
MLK2, MLK3 and DLK represents the dominant kinases for
MKK7 (Gallo and Johnson, 2002). Importantly, siRNAs against
MLK3, but not MLK2 or DLK, abolished PIK3R1R348*-induced
p-JNK (Figure 3F; Figures S3F and S3G). It is noteworthy that nu-
clear p-MKK7 was also decreased; however, depletion of MLK3
did not inhibit nuclear translocation of total MKK7, suggesting
that MKK7 nuclear translocation is independent of MLK3 and
MKK7 phosphorylation. PIK3R1R348* induced a redistribution
of MLK3 from the cytosol to the nucleus (Figure 3G). In addition,
serine and threonine phosphorylated MLK3 was increased by
PIK3R1R348* exclusively in the nucleus, but not in the cytosol
(Figure 3H). These data suggest that activation of JNK signaling
by PIK3R1R348* is initiated in the nucleus and this activation in-
volves nuclear translocation and subsequent phosphorylation
of MLK3 and MKK7.
p85a R348* and L370fs Localize to the Nucleus
Next, we investigated whether the localization of p85a R348*
correlates with nuclear accumulation of MKK7 and MLK3. WT
p85a and p85a E160* localized predominantly in the cytosol (Fig-
ures 4A and 4B). Strikingly, p85a R348* was readily detected in
the nucleus. p85a L370fs, which activated ERK and JNK in
OVK18, also localized to the nucleus (Figure S4A). Localization
of p110a was not altered by WT p85a, which does not enter
the nucleus or by p85a R348*, which does not bind p110
(Figure S4B).
To gain insight into mechanisms underlying nuclear transloca-
tion of p85a R348*, we mapped the domain that enables nuclear
translocation using a series of truncation p85a mutants. Four
truncation mutants downstream of R348* failed to translocate
to the nucleus (Figures S4C–S4E). Furthermore, these four muta-
tions failed to activate MAPKs or promote IL-3 independent sur-
vival of BaF3 (Figures S4F and S4G). Two mutants upstream of
R348* between the BCR homology (BH) domain and the nSH2
Cancer Cell
p85a Neomorphic Mutants Activate MAPK Pathwaydomain, N299* and N324*, localized to the nucleus (Figures 4C
and 4D; Figure S4H). Importantly, similar to PIK3R1R348*, these
two mutations induced p-ERK and p-JNK (Figure 4E) and IL-3-
independent survival of BaF3 (Figure 4F). In contrast, truncation
mutants within the BH domain (R188*, E212*, Q235*, E266*) did
not translocate to the nucleus, induceMAPK phosphorylation, or
mediate survival of BaF3.
To determine whether nuclear localization of p85a mutants
was essential for activation of the JNK signaling cascade, a nu-
clear export signal (NES) was engineered into the N-terminal end
of p85a R348* and p85a N324* to exclude them from the nu-
cleus. These NES-containing mutants retained the ability to acti-
vate B-Raf, MKK1/2 and ERK (Figure 4G; Figures S4I and S4J),
consistent with this occurring in the cytosol. In contrast, activa-
tion of the JNK signaling cascade, including phosphorylation of
c-Jun, JNK, MKK7 and MLK3 was impaired in NES-containing
mutants (Figures 4G and 4H). In addition, these NES-containing
mutants did not induce nuclear translocation of MKK7 andMLK3
(Figure 4G). Taken together, these results reinforce the conten-
tion that p85a R348* mediates the nuclear accumulation of
MLK3 and MKK7 thereby promoting activation of the JNK
signaling cascade in the nucleus. In contrast, activation of ERK
does not rely on nuclear localization of p85a R348*.
p85a R348* Translocates into the Nucleus through
Binding to Cdc42 and Rac1, which Are Required for
Activation of ERK and JNK
p85a does not contain a consensus intrinsic nuclear localization
signal (NLS). As shown in Figure 4D, an intact BH domain ap-
pears to be necessary for nuclear localization of p85a mutants.
This domain contains conservedmotifs that bind small GTPases,
including Cdc42 and Rac1 (Tolias et al., 1995; Zheng et al.,
1994). Furthermore, Rac1 and Cdc42 contain canonical NLS
and contribute to ERK and JNK activation (Etienne-Manneville
and Hall, 2002; Teramoto et al., 1996), making these small
GTPases plausible candidates to translocate R348* to the nu-
cleus. As expected, an intact BH domain in WT and mutated
p85a was required for binding to Cdc42 and Rac1 (Figure 5A).
We did not detect RhoA binding to WT or mutant p85a. Remark-
ably, Cdc42 or Rac1 siRNAs, but not RhoA siRNAs, reduced nu-
clear p85a R348* levels (Figure 5B; Figures S5A–S5C) without
affecting total p85a R348* levels (Figure S5D). Combined knock-
down of Cdc42 and Rac1 further inhibited nuclear translocation
of p85a R348* (Figure 5B; Figure S5C), suggesting that both
Cdc42 and Rac1 contribute to nuclear translocation of p85a
R348*.
Along with decreased nuclear translocation of p85a R348*,
Cdc42, or Rac1 siRNAs inhibited nuclear translocation of
MKK7 and MLK3 (Figure 5C; Figure S5E). These siRNAs also in-
hibited PIK3R1R348*-induced phosphorylation of MLK3, MKK7,
JNK, c-Jun, B-Raf, MKK1/2, and ERK, with combined knock-
down producing a further reduction (Figures S5D, S5F, and
S5G). Similar to siRNA, expression of dominant negative
Cdc42 (T17N) or Rac1 (T17N) abrogated PIK3R1R348*-induced
ERK (Figures 5D and 5E) and JNK (Figures 5D and 5F) signaling
cascades, suggesting a requirement for Rac1 and Cdc42
GTPase activities. Notably, nuclear translocation of p85a
R348*, MKK7, and MLK3 was not abolished by dominant-nega-
tive Rac1 and Cdc42 (Figure 5D). Therefore, physical interactionCwith Cdc42 andRac1 appears sufficient for nuclear translocation
of p85a R348*, MKK7, and MLK3, whereas active Cdc42 and
Rac1 are essential for initiation of the signaling cascade.
p85a R348* and L370fs Are Scaffolds for a
MLK3/MKK7/JNK1/JNK2 Complex to Promote
Nuclear JNK Signaling
Because Cdc42 and Rac1 are required for nuclear localization
of p85a R348*, and R348*, in turn, is required for the nuclear
translocation of MKK7 and MLK3, we speculated that these
molecules exist as a complex in the nucleus. Indeed, p85a
R348* co-immunoprecipitated with Cdc42, Rac1, MKK7, and
MLK3 from nuclear extracts (Figures 6A and 6B). Interestingly,
JNK1 and JNK2 were also present in the immunoprecipitates
(Figures 6A and 6B). Notably, this nuclear complex formation
was drastically reduced upon exclusion of p85a R348* from
the nucleus by NES addition (Figure 6B), consistent with p85a
R348* being required for assembly of a stable nuclear MLK3/
MKK7/JNK1/JNK2 complex. The assembly of this nuclear com-
plex was also observed in OVK18 in the context of p85a L370fs,
but not in HEC108, where p85a did not localize to the nucleus
(Figure S6A).
To further characterize the nuclear R348* complex, gel filtra-
tion experiments were conducted. Whereas a small portion of
p85a R348* eluted in fractions 34–36, the majority of nuclear
R348* was recovered in a large molecular complex (fractions
25–29), which also contained JNK1, JNK2, MKK7, MLK3,
Cdc42, and Rac1 (Figure 6C). Immunoprecipitation confirmed
that these proteins formed a physical complex in fractions 25–
29, but not fractions 34–36 (Figure 6D). Strikingly, excluding
R348* from the nucleus by NES addition led to an absence of
detectable MKK7/MLK3 and JNK1/2 in fractions 25–26 and
Cdc42/Rac1 in fraction 25 (Figure 6E). In the absence of nuclear
p85a R348*, JNK1 coprecipitated with MLK3 and MKK7, but not
JNK2, Cdc42, or Rac1 (Figure 6F). These results together sup-
port the notion that nuclear p85a R348* stabilizes a MLK3/
MKK7/JNK1/JNK2 nuclear complex.
The p85a R348*/Cdc42/Rac1/MLK3/MKK7/JNK1/JNK2
Complex Can Be Detected in the Cytosol
To determine whether the JNK signaling complex could form in
the cytosol and translocate to the nucleus, gel filtration and
immunoprecipitation were also performed with cytosolic ex-
tracts. p85a R348* was present in fractions 29–33 and associa-
tion of R348* with Cdc42, Rac1, and MLK3/MKK7/JNK1/JNK2
was detected in fraction 29, which was the only fraction where
these molecules comigrated (Figures S6B and S6C). Excluding
R348* from the nucleus resulted in cytosolic accumulation of
R348*, MLK3, MKK7, JNK1, and JNK2 (fractions 25–29; Fig-
ure S6D). Interestingly the migration of Rac1 and Cdc42 was
not altered, suggesting that these are normally part of large com-
plex. Furthermore, all of the components of the complex were
readily detectable by coimmunoprecipitation in fractions 25–29
(Figure S6E). Taken together, these results suggest that p85a
R348* functions as a scaffold protein that assembles and stabi-
lizes a complex of Cdc42, Rac1, MLK3, MKK7, and JNK1 and
JNK2 in the cytosol. The stabilized complex then translocates
to the nucleus for efficient and robust activation of the JNK
pathway.ancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc. 483
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Cancer Cell
p85a Neomorphic Mutants Activate MAPK PathwayPIK3R1R348* and PIK3R1L370fs Promote Malignant
Phenotypes through ERK and JNK Signaling In Vitro
and In Vivo
To determine the functional relevance of ERK and JNK activation
by PIK3R1R348*, we established two independent stable endo-
metrial cancer cell lines (Figure S7A) with results obtained from
the two clones being essentially identical. PIK3R1R348* stable
clones demonstrated increased JNK and ERK phosphorylation
(Figure S7A) as well as increased proliferation assayed by bro-
modeoxyuridine incorporation (Figure 7A), which was decreased
by a MEK inhibitor, but not a JNK inhibitor (Figure 7A; Fig-
ure S7B), suggesting that PIK3R1R348* induces proliferation
through MEK/ERK activation. Inhibition of cell proliferation by
the MEK or JNK inhibitor did not reach statistical significance
in LacZ-,PIK3R1WT-, orPIK3R1E160*-expressing cells (Figure 7A;
Figure S7B). The JNK pathway can induce or inhibit apoptosis
depending on the cellular context. In the presence of FAS ligand,
LacZ-, PIK3R1WT-, or PIK3R1E160*-expressing cells underwent
apoptosis as indicated by DNA fragmentation (Figure 7B; Fig-
ure S7C). In contrast, PIK3R1R348*-expressing cells were insen-
sitive to this apoptotic stimulus. This anti-apoptotic effect was
reversed by a JNK inhibitor, but not a MEK inhibitor (Figure 7B;
Figure S7C), suggesting that PIK3R1R348* protects cells from
apoptosis through JNK activation. Strikingly,PIK3R1R348* clones
were 3-fold more invasive than PIK3R1WT clones in Matrigel-
coated Boyden chamber transwells (Figure 7C). Expression of
PIK3R1R348* also resulted in larger spheroids and higher cell
viability in 3D Matrigel cultures (Figure 7D). These effects were
suppressed by ERK and JNK inhibition (Figures 7C and 7D).
Together, these data indicate that PIK3R1R348* increases cells
proliferation and invasion and decreases sensitivity to apoptosis
through activation of ERK and JNK pathways.
To determine whether the in vitro effects on growth and
invasiveness were recapitulated in vivo, LacZ-, PIK3R1WT-,
PIK3R1E160*-, and PIK3R1R348*-expressing isogenic endome-
trial cancer cell lines were injected subcutaneously into nude
mice. Expression of PIK3R1R348* significantly increased tumor
growth as compared to LacZ- or PIK3R1WT-expressing cells at
week 3 (p < 0.05; Figure 7E). In accord with the in vitro and pa-
tient data, PIK3R1R348*-expressing tumors showed marked
elevation of p-ERK and p-JNK (Figure S7D). These PIK3R1R348*-
driven tumors were more sensitive to MEK and JNK inhibitors
than PIK3R1WT- and PIK3R1E160*-expressing tumors as indi-
cated by percent tumor growth inhibition (Figure 7F). Strikingly,
OVK18 xenografts that have naturally occurring PIK3R1L370fs
were also highly sensitive to the MEK and JNK inhibitors
(Figure S7E), further supporting the rationale for therapeutic tar-Figure 2. PIK3R1R348*- and PIK3R1L370fs Mutant Cell Lines and Endom
(A) Top, schematic showing the locations of p85a siRNA-targeted regions; Botto
non-specific (NS) control for 72 hr were cultured in the absence of FBS (0% FBS
factor (EGF; 10 ng/ml) or insulin-like growth factor 1 (IGF-1; 10 ng/ml) for another
gels due to sample well limits but the membranes were probed with same antibo
time.
(B) Western blotting of total lysates or subcellular fractions from SKUT2 endom
KRASG12D. a-Tubulin (cytosolic), pan-cadherin (membrane), and histone H3 (nuc
(C and D) Immunohistochemical staining for p-ERK (C) and p-JNK (D) in four e
without PIK3R1R348* (control). Nuclei were counterstained in hematoxylin. Scale
See also Figure S2 and Table S4.
Cgeting of PIK3R1R348* or neighboring mutations with MAPK
pathway inhibitors.
DISCUSSION
The effective implementation of targeted therapy ultimately lies
in the individualization of treatment regimens based on effec-
tively targeting the effects of driver mutations in cancer.Whereas
current approaches focus on the discovery of targetable cancer
genes, the drug screening and mechanistic studies herein sug-
gest that the specific aberration in the cancer gene rather than
the cancer gene alone should be considered for effective thera-
peutic targeting. The effect of particular mutations may not only
demonstrate a quantitative effect on drug sensitivity but also a
qualitative effect changing the function of the molecule and
potentially requiring different therapeutic approaches (Chen
et al., 2004; Lutzky et al., 2008; Lynch et al., 2004; Ward et al.,
2010). We demonstrate that PIK3R1R348* and the neighboring
mutation PIK3R1L370fs represent neomorphic p85a mutations
that could potentially be biomarkers of responsiveness to inhib-
itors targeting the ERK and JNK pathways. Our observations that
the naturally occurring PIK3R1L370fs exhibited the same effects
of PIK3R1R348* strengthen the pathophysiological significance
of the findings andmore importantly indicate thatPIK3R1 trunca-
tion mutations in proximity to R348* exhibit the same pheno-
types and therapeutic liabilities. Because PIK3R1R348* is the
most common recurrent PIK3R1 mutations in endometrial can-
cers (9.6% and 6.9% of all PIK3R1 mutations in our and TCGA
data sets, respectively; Cheung et al., 2011; Kandoth et al.,
2013) and colon cancers (16.6%; TCGA; Cerami et al., 2012)
with multiple truncation and other mutations in PIK3R1 in prox-
imity, approaches to benefit patients with these aberrations are
needed.
The primary function of p85 regulatory subunits is to stabilize
and to maintain p110 catalytic subunits of PI3K in a quiescent
state until activated by receptor tyrosine kinases (Cuevas
et al., 2001; Yu et al., 1998). PIK3R1R348* and PIK3R1L370fs are
different from the other naturally occurring PIK3R1 mutations
characterized because they activate not only the PI3K pathway,
but also specific components of the MAPK pathway. The mech-
anism by which the PI3K pathway is activated warrants further
investigation; this could be a result of interaction of the neo-
morphs with Cdc42 and Rac1, which can impinge on the PI3K
pathway (Murga et al., 2002). However, the activation of the
MAPK pathway by PIK3R1R348* and PIK3R1L370fs is independent
of the conventional role of PIK3R1 in PI3K signaling because the
activation was insensitive to PI3K or AKT inhibitors. This is furtheretrial Tumors Show High Levels of p-ERK and p-JNK
m, ovarian endometrioid cancer cells OVK18 transfected with p85a siRNAs or
) for an additional 24 hr. The cells were then simulated with epidermal growth
1 hr before being harvested for western blotting. Lysates were loaded into two
dies for equal duration and the proteins were detected under same exposure
etrial cancer cells transfected with PIK3R1WT, PIK3R1E160*, PIK3R1R348*, or
lear) served as markers for purity of fractions.
ndometrial carcinomas carrying PIK3R1R348* and 12 endometrial carcinomas
bar represents 50 mm.
ancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc. 485
p-MKK4
MKK3
MKK4
p-MKK1/2
MKK1/2
p-MKK3/6
p-MKK7
MKK7
Cytosol Nucleus
p-MKK1/2
MKK1/2
p-MKK7
MKK7
p-ERK1/2 
ERK1/2
NS 
siRNA
MKK4 
siRNA#1
MKK1 
siRNA#1
MKK7 
siRNA#1
MKK2 
siRNA#1
p-JNK
JNK
A B
C D
p-ERK1/2 
ERK1/2
p-MKK1/2 
MKK1
NS 
siRNA
B-Raf
siRNA#1
c-Raf
siRNA#1
E F
IP: B-Raf
WB: pThr
WB: pSer
WB: pTyr
WB: B-Raf
NS 
siRNA
DLK
siRNA#1
MLK2 
siRNA#1
MLK3 
siRNA#1
p-JNK
JNK
p-MKK7
MKK7
G
Cytosol
Nucleus
Total lysate
IP: MLK3
WB: pThr
WB: pSer
WB: pTyr
WB: MLK3
H NucleusCytosol
IP: MLK3
WB: pThr
WB: pSer
WB: pTyr
WB: MLK3
Figure 3. PIK3R1R348* Selectively Activates B-Raf-MKK1/2-ERK and MLK3-MKK7-JNK Pathways
(A) Total lysates from transfected SKUT2 were analyzed with western blotting.
(B) Cells cotransfected with PIK3R1WT, PIK3R1R348* or KRASG12D and 20 nM siRNAs targeting the MKKs or nonspecific (NS) control for 72 hr were harvested for
subcellcular fractionation. Western blots shown were from nuclear lysates.
(C) Transfected SKUT2 were harvested for subcellcular fractionation and western blotting.
(D) Cells were cotransfectedwithPIK3R1WT,PIK3R1R348*, orKRASG12D and 10 nM siRNAs targeting B-Raf, c-Raf, or NS control for 72 hr. Data shown arewestern
blots of cytosolic lysates.
(legend continued on next page)
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p85a Neomorphic Mutants Activate MAPK Pathwaysupported by p85a R348* and L370fs lacking the iSH2 domain
that mediates association with p110. The N-terminal region of
p85a is thought to contribute to PI3K activity-independent func-
tions of PIK3R1. We and others have recently shown that p85a
forms a homodimer that binds to and regulates PTEN (Cheung
et al., 2011; Taniguchi et al., 2006). p85a also interacts with small
GTPases of the Rho family to regulate cytokinesis (Garcı´a et al.,
2006). Moreover, PIK3R1WT mediates insulin-induced activation
of JNK via Cdc42 and MKK4 (Taniguchi et al., 2007). The sig-
naling cascade by which PIK3R1R348* activates JNK is MKK7-
dependent and is distinct from that proposed for the actions of
PIK3R1WT (Taniguchi et al., 2007).
Perhaps the most striking neomorphic characteristic of p85a
R348* and L370fs is the prominent nuclear localization that
promotes JNK signaling. Nuclear translocation of the neo-
morphs requires an intact BH domain and is blocked by p85a
SH2 domains. The p85a SH2 domains mediate interaction with
cytoskeletal regulatory proteins such as FAK (Bachelot et al.,
1996) and phosphotyrosine-containing peptides, such as recep-
tor tyrosine kinases (Hellyer et al., 1998; McGlade et al., 1992;
Pandey et al., 1994). Physical linkage to these cytoskeletal and
membranous proteins may prohibit p85a from translocating
into the nucleus. In a search for nuclear transport chaperones,
we demonstrated that Rac1 and Cdc42, which bind p85a via
its BH domain (Tolias et al., 1995; Zheng et al., 1994), were
required for nuclear translocation of p85a R348*. Interestingly,
both Rac1 and Cdc42, which carry canonical NLS (K-K/R-x-K/
R), have been proposed to act as nuclear transport chaperones
for STAT5 (Kawashima et al., 2006), SmgGDS (Lanning et al.,
2003), p120 catenin (Lanning et al., 2003), and ACK (Ahmed
et al., 2004). Rac1 also acts as transcriptional coactivator
through associating with transcription factors in the nucleus
(Buongiorno et al., 2008; Kawashima et al., 2006; Lanning
et al., 2003) and nuclear Cdc42 regulates chromosome dy-
namics (Lagana et al., 2010; Yasuda et al., 2004). Nuclear import
of Cdc42 and Rac1 may also be facilitated through binding to
other effectors harboring NLS, such as PAR family members (Jo-
hansson et al., 2000). Indeed, as indicated in our gel filtration
studies, Cdc42 and Rac1 are consistently present in large phys-
ical complexes.
Importantly, in addition to providing a physical link for nuclear
localization of the complex, Cdc42 and Rac1 activity is required
to induce ERK and JNK signaling cascades. Our data are consis-
tent with Cdc42 and Rac1 increasing MLK3 activity, resulting in
JNK activation (Teramoto et al., 1996). Although MLK3 has been
shown to mediate B-Raf-induced ERK activation (Chadee and
Kyriakis, 2004), it is unlikely in our model because PIK3R1R348*-
induced phosphorylation of MLK3 only occurred in the nucleus.
Rather, PIK3R1R348*-induced ERK activation most likely requires
unidentified downstream effectors of Cdc42 or Rac1. In this re-
gard, PAK, which is a Cdc42 and Rac1 target, has been demon-(E) Total lysates from transfected SKUT2 were harvested for immunoprecipitatio
used as control.
(F) Cells cotransfected with PIK3R1WT, PIK3R1R348*, or KRASG12D and 20 nM siRN
for subcellular fractionation. Western blots shown were from nuclear lysates.
(G) Western blots for MLK3 in total lysates, cytosolic and nuclear fractions from
(H) Western blots of IP with anti-MLK3 antibody using cytosolic and nuclear extr
See also Figure S3.
Cstrated to activate the Raf/ERK cascade (Koh et al., 2009). The
BH domain of p85a shares high homology to the Rho GTPase-
activating protein domain of the breakpoint cluster region (bcr)
protein, which inactivates Rho family proteins. There are conflict-
ing data on the regulation of Cdc42 and Rac1 activity by p85a.
Wild-type p85a has been shown to increase (Taniguchi et al.,
2007), decrease (Chamberlain et al., 2004; Stankiewicz et al.,
2010), or have no effect (Zheng et al., 1994) on the activity of
Cdc42 or Rac1. It is possible that both an intact N terminus
and functional SH2 domains are required forWT p85a to regulate
the activity of Rho GTPases (Taniguchi et al., 2007). We also
found that p85a R348*, which lacks SH2 domains, was not suf-
ficient to alter GTP binding or expression level of Cdc42 or Rac1
in either the cytosol or nucleus (our unpublished observations). It
is possible that basal activity of Cdc42 and Rac1 is sufficient to
support the effects of PIK3R1R348*.
p85a R348* and L370fs appear to be scaffolds that coordi-
nate the formation of a stable MLK3/MKK7/JNK1/JNK2 com-
plex. From structural features, we speculate that p85a R348*
and L370fs directly bind MLK3 through conserved proline-rich
and SH3 domains (Zhang and Gallo, 2001). Interestingly, the
SH3 domain of p85a shares high homology with that of JIP1,
which is a known scaffold for the MLK/MKK/JNK complex and
binds MKK7 via its SH3 domain (Dickens et al., 1997). Thus
the SH3 domain in p85a R348* and L370fs may also bind
MKK7. Because p85a lacks an obvious consensus JNK-binding
domain, JNK is likely to be tethered to the complex through an
interaction with MKK7 or other intermediary proteins. Moreover,
as JIP-1 causes cytosolic retention of JNK (Dickens et al., 1997),
it is conceivable that p85a R348* and L370fs displace the cyto-
solic MLK3/MKK7/JNK from the JIP1 scaffold, allowing nuclear
translocation. The recruitment and stabilization of a MLK3/
MKK7/JNK1/JNK2 complex in the nucleus may be required
for nuclear JNK activation. Indeed, while the p85a R348*/
Rac1/Cdc42/MLK3/MKK7/JNK1/JNK2 complex can be de-
tected in the cytosol, particularly when R348* is excluded from
the nucleus, phosphorylated forms of JNK, MLK3, and MKK7
are highly enriched in the nuclear compartment. Thus, either
an active complex is formed in the cytosol and then rapidly
translocated to the nucleus or MKK7 and JNK1/2 are rapidly de-
phosphorylated in the cytosol. Alternatively, phosphorylation of
complex components occurs primarily in the nucleus. Differen-
tial binding partners in the complex between cytosol and nu-
cleus may account for this specificity. Indeed, although we
demonstrated the presence of multiple molecules in the com-
plex in the cytosol and the nucleus, the sizes of the complexes
were different in both compartments. Furthermore, the large
size of the complexes suggests that additional molecules are
likely present in the complex. Their identities as well as their
roles in the functional activity of the neomorphs remain to be
identified.n (IP) with anti-B-Raf antibody and western blotting (WB). IP with anti-IgG was
As targeting MLK2, MLK3, DLK (40 nM), or NS control for 72 hr were harvested
transfected SKUT2.
acts from transfected SKUT2.
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Figure 4. p85a R348* Localizes to the Nucleus and Activates MLK3-MKK7-JNK Signaling in the Nucleus
(A and B) SKUT2 cells transfected with HA-tagged PIK3R1WT, PIK3R1E160*, or PIK3R1R348* were harvested for subcellular fractionation and western blotting (C,
cytosolic; M, membrane; N, nuclear) (A) or immunostaining using anti-HA (green) antibody (B). DAPI was used for nuclear staining. ‘‘Merge’’ indicates combined
images. Scale bar represents 10 mm.
(C) Schematic illustration of PIK3R1 truncation mutations upstream of R348*.
(D and E) Cell lysates from SKUT2 cells transfected with indicated mutants were subjected for subcellular fractionation as in (A) (D) or western blotting (E).
(F) BaF3 cells transfected with PIK3R1WT or PIK3R1 mutant were cultured without IL-3 for 4 weeks prior to viability assay. Means (±SD) of triplicates from three
independent experiments are shown.
(G and H) SKUT2 transfected with PIK3R1WT, PIK3R1N324*, PIK3R1R348*, or PIK3R1N324* and PIK3R1R348* fused with nucleus export signal (NES) were harvested
for subcellular fractionation and WB (G) or IP with anti-MLK3 antibody in nuclear extract and analyzed by WB (H). *p < 0.05, compared with PIK3R1WT. Control,
parental SKUT2.
See also Figure S4.
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Figure 5. Cdc42 and Rac1 Mediate Nuclear Entry of p85a R348* and Activation of ERK and JNK Signaling Cascades by p85a R348*
(A) Total lysates from SKUT2 transfected with HA-tagged PIK3R1WT or mutants were harvested for IP with anti-HA antibody andWB. IP with anti-IgGwas used as
control.
(B and C) Cells cotransfected with PIK3R1R348* and 20 nM each of the indicated siRNAs for 72 hr were harvested for subcellular fractionation (C, cytosolic; M,
membrane; N, nuclear) and WB.
(D–F) Cells cotransfected with PIK3R1R348* and dominant negative (DN)-Cdc42, -Rac1, or -RhoA for 72 hr were harvested for subcellular fractionation (D) or total
lysates used for IP with anti-B-Raf antibody (E) or nuclear lysates used for IP with anti-MLK3 antibody (F).
See also Figure S5.
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p85a Neomorphic Mutants Activate MAPK PathwaySignaling specificity, such as strength, duration, and location
of activation, determines the functional consequences of
MAPK signaling (Inder et al., 2008). The pro- and anti-apoptotic
signals transmitted by JNK are an archetype of this phenomenon
(Dhanasekaran and Reddy, 2008). We found that activation of
JNK in the nucleus renders cells resistant to FAS-induced
apoptosis. Thus, exclusive activation of JNK in the nucleus
may serve to explain the functional consequences of the nuclear
localization of p85a R348* and L370fs and the selection of these
mutations during tumorigenesis. Blocking ERK and JNK in-
hibited PIK3R1R348*- and PIK3R1L370fs-induced tumorigenic
phenotypes. Indeed, whether combined inhibition of the PI3K
pathway, MEK, and/or JNK signaling are required to achieve
maximal suppression of the tumorigenic function of these
PIK3R1 neomorphs warrants further study and will provide pre-Cclinical data required to develop trials to treat patients with
aberrations in this region of PIK3R1. In endometrial cancer, co-
mutations in PI3K pathwaymembers occur at frequencies signif-
icantly higher than predicted, suggesting that comutations in
different components of the PI3K pathway may cooperate for
efficient transformation (Cheung et al., 2011; Oda et al., 2008).
Interestingly, PTEN or PIK3CA mutations co-occur at a fre-
quency higher than expected with PIK3R1R348* in both our in-
house (five of five PIK3R1R348*-tumors) and TCGA endometrial
cancer cohorts (seven of eight PIK3R1R348*-tumors). In contrast,
KRAS mutation and PIK3R1R348* did not co-occur in our in-
house cohort (zero of five PIK3R1R348*-tumors) and they co-
occurred at the expected frequency based on the prevalence
of each independent mutation in TCGA cohort (four of eight
PIK3R1R348*-tumors).ancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc. 489
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Figure 6. p85a R348* Acts as a Scaffold to Assemble a Cdc42/Rac1/MLK3/MKK7/JNK1/JNK2 Complex
(A) Nuclear lysates from SKUT2 cells transfected with HA-tagged PIK3R1R348* were subjected to IP with anti-HA antibody and WB.
(B) Nuclear lysates from SKUT2 transfected with HA-tagged PIK3R1WT, PIK3R1R348*, or nucleus export signal (NES)-fused PIK3R1R348* were subjected to IP with
anti-JNK1 antibody.
(C and D) Nuclear extract from SKUT2 transfected with HA-tagged PIK3R1R348* was fractionated using gel filtration column. The indicated fractions were
analyzed with WB (C) or pooled for IP with anti-HA antibody (D).
(E and F) Nuclear extract from SKUT2 transfected with HA-tagged NES-PIK3R1R348* was fractionated using gel filtration. The indicated fractions were analyzed
(E) with WB or pooled for IP with anti-JNK1 antibody (F). F, fraction; MW, molecular weight.
See also Figure S6.
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p85a Neomorphic Mutants Activate MAPK PathwayWith the advent of therapies targeting the PI3K and MAPK
pathways and genomic profiling, there is a tremendous interest
in identifying biomarkers that can select cancer patients most
likely to benefit from targeted therapy. The ability of PIK3R1R348*
and PIK3R1L370fs to selectively activate the MEK and JNK path-
ways and to potentially bypass effects of PI3K pathway inhibitors
similar to KRAS suggests that caution should be used in enrolling
these patients into PI3K targeted clinical trials. It may be neces-
sary to treat patients with PIK3R1R348*, PIK3R1L370fs, or neigh-490 Cancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc.boring PIK3R1 mutations using similar approaches to patients
with combined RAS and PI3K pathway mutations, a common
observation in endometrial and colon cancers. Finally, if neomor-
phic mutation is a generalizable phenomenon with many other
mutations in cancer genes also acting as neomorphs, this
provides a note of caution in the application of targeted thera-
pies. In this case, it will be likely that the implementation of
approaches to functionally characterize the effects of patient-
specific mutations will be needed to fulfill the promise of
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Figure 7. PIK3R1R348* Promotes Malignant Phenotypes In Vitro and In Vivo through ERK and JNK
(A) SKUT2 stably expressing LacZ, PIK3R1WT, PIK3R1E160*, or PIK3R1R348* were cultured in medium containing 1% FBS with or without MEK inhibitor
PD0325901 (PD) at 20 nM. DMSO served as negative control. Cell proliferation was determined at 24, 48, and 72 hr after seeding.
(B) Stable SKUT2were cultured inmedium containing 5%FBS (control) or anti-Fas antibody (+FAS) with or without JNK inhibitor SP600125 (SP) at 20 mM for 72 hr
before apoptosis assay.
(legend continued on next page)
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EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
Endometrial cancer cell lines and BaF3 were cultured as reported (Cheung
et al., 2011). Ovarian cancer cell line OVK18 from the Riken BioResource Cen-
ter (Japan) was cultured in minimum essential media with 10% fetal bovine
serum (FBS). Generation of stable isogenic SKUT2 cell lines is described in
the Supplemental Experimental Procedures. Stable BaF3 cell lines were
selected with blasticidin (20 mg/ml) and IL-3 withdrawal and were maintained
in medium without IL-3. IGF-1 and EGFR ligands were from R&D Systems.
SP600125 and PD0325901 for in vitro assays were from Sigma-Aldrich. The
145-compound library was obtained from the John S. Dunn Gulf Coast Con-
sortium for Chemical Genomics. For in vivo studies, GSK1120212B and
GDC0973 were from the PI3K in Women’s Cancer Stand up to Cancer Project;
BI78D3 was from Santa Cruz Biotechnology. PD0325901 and SB203580 were
from LC Laboratories.
BaF3 Cytotoxicity Assay
The day before treatment, stable BaF3 cells (1 3 104) were seeded in 96-well
plates in medium with or without IL-3. Cells were treated with DMSO or inhib-
itors (1 nM to 10 mM) in the presence or absence of IL-3 for 72 hr. Cell viability
was determined using PrestoBlue (Promega). Two independent experiments,
each in duplicate, were performed.
Cell Extract Preparation, Immunoprecipitation, and Western
Blotting
Cytosol, membrane, and nuclear fractions were prepared using FractionPREP
Cell Fractionation kit (BioVision). Whole-cell lysates for western blotting were
extracted with RIPA (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS, protease, and phosphatase inhibitor cock-
tail). Cell lysates (25 mg) were loaded onto SDS-PAGE and transferred to a pol-
yvinylidene fluoride membrane and protein expression was depicted with an
enhanced chemiluminescence western blot detection kit (Amersham Biosci-
ences). Whole-cell lysates for immunoprecipitation were prepared using lysis
buffer containing 0.5% NP-40, 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM
EDTA pH 8, and protease inhibitors. Nuclear extracts for immunoprecipitation
was prepared using Nuclear Complex Co-IP Kit (Active motif). The lysates
were precleared by incubating with 1:1 slurry of protein A/G agarose (Santa
Cruz Biotechnology) for 1 hr at 4C, and then immunoprecipitated with anti-
bodies against HA, B-Raf, MLK3, or JNK1 overnight at 4C. The immune com-
plexes were collected by incubation with protein A/G agarose for 4 hr before
being resolved by SDS-PAGE. Normal IgG was used as negative control. An-
tibodies used are listed in the Supplemental Experimental Procedures.
Human Endometrial Tumor Samples and Immunohistochemistry
The endometrial cancer patient samples have been described previously
(Cheung et al., 2011). After informed consent, patient materials were collected
according to an Institutional Review Board-approved protocol at MD Ander-
son Cancer Center (MDACC). Immunohistochemistry was performed in the
Histology and Tissue Processing Facility Core at MDACC. Intensity of nuclear
staining was evaluated by a pathologist (Dr. R. Broaddus). All histological(C) Representative images (left) and mean number of invaded cells of five field
indicated inhibitors.
(D) Representative images (left) and cell viability (right) of indicated SKUT2 cells gr
for another 3 days.
(E) Cells were subcutaneously injected into mouse flank regions (n = 12/group).
(F) Tumor-bearing mice were treated with vehicles, MEK inhibitor GSK1120212b
growth inhibition percentages were calculated and presented in the graph.
Scale bars represent 50 mm (C and D). All in vitro assays were performed with two
of triplicates from three independent experiments are shown. All in vivo data are r
DMSO control; ***p < 0.05 compared with PIK3R1WT DMSO control. #p < 0.05 com
at same time point; ###p < 0.05 compared with PIK3R1WT treated with correspon
492 Cancer Cell 26, 479–494, October 13, 2014 ª2014 Elsevier Inc.studies were performed in a blinded manner with regard to the sample genetic
context.
Mice
All animal experiments were approved by MDACC’s Institutional Animal Care
and Use Committee. Animal care was followed according to institutional
guidelines. Detailed experimental procedures are provided in the Supple-
mental Experimental Procedures.
Statistical Analysis
All experiments were independently repeated at least twice. Data of the
in vitro assays were derived from triplicates of three independent experiments
and are presented as means ± SD. The significance of differences was
analyzed with Student’s t test. Significance was accepted at the 0.05 level
of probability (p < 0.05).
Additional experimental protocols are described in the Supplemental Exper-
imental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.08.017.
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